Research Compounds & Reference Data

Tirzepatide mimics two naturally occurring gut hormones — GIP and GLP-1. Research documents that together they slow gastric emptying, reduce appetite signalling, act on blood sugar regulation pathways, and act on the brain's satiety centres. Research data documents metabolic pathway effects in comparative trials with semaglutide.

Reference concentration of 2.5mg as noted in research. Escalation parameters are documented in published clinical literature. Nausea and mild GI effects in the first few weeks are commonly noted in research and documented as resolving in the majority of research subjects. Administration parameters are documented in published clinical literature.

Semaglutide is a GLP-1 receptor agonist that mimics the natural hormone GLP-1, released after eating. Research documents that it slows digestion, increases satiety signalling, reduces appetite signals from the brain, and acts on blood sugar regulation pathways. Research notes it targets both gut hormone pathways and the brain's reward centre, with food reward signalling pathway effects documented in research data.

Reference concentration noted at 0.25mg as noted in research. Escalation parameters are documented in published research literature. Nausea is documented in research as resolving in the majority of research subjects within 2–4 weeks of each concentration increase. Research notes consistent weekly timing regardless of meals. Research data notes outcomes are documented alongside dietary and lifestyle variables in published studies.

Retatrutide activates three hormone receptors simultaneously. Research notes GLP-1 activation is associated with reduced appetite signalling and slowed digestion. GIP activation is associated with enhanced insulin response and fat metabolism pathway effects. Glucagon activation is documented to increase metabolic rate and act on fat mobilisation pathways — including visceral and hepatic fat. Phase 2 trials documented 24% body weight reduction observed over 48 weeks in published research — as documented in published Phase 2 research data.

Reference concentration noted at 2.5mg as noted in research. Escalation parameters are documented in published research literature. GI side effects are noted in early research data — research documents these as resolving in the majority of research subjects. Glucagon activation is noted in research as associated with heart rate pathway activity. Research notes combination with other GLP-1 agents is not documented in published research combinations.

Amylin is a hormone co-secreted with insulin after meals that acts on satiety signalling pathways in the brain. Research documents that Cagrilintide mimics this satiety signal continuously, with caloric intake reduction noted as an observed effect in research data. Unlike GLP-1 agents, it acts primarily on the hypothalamus and brainstem via a distinct neural pathway. When combined with a GLP-1, research data notes the effect is additive — CagriSema studies document additive metabolic pathway effects in published research.

Reference concentration noted at 0.25mg as noted in research. Escalation parameters are documented in published research literature. Research documents combination with semaglutide in CagriSema trials. Research notes the amylin pathway mechanism acts on satiety signalling centres independent of dietary variables.

Retatrutide is a triple receptor agonist activating GLP-1, GIP, and glucagon simultaneously, with fat mobilisation and appetite signalling pathway effects documented in published data. Tirzepatide adds synergistic GIP/GLP-1 dual action, with compounding appetite signalling and metabolic pathway data documented in research. Administration parameters for combination use are documented in published research data. Tesofensine works through an entirely different mechanism, acting on the reuptake of dopamine, norepinephrine, and serotonin in the brain, with CNS hunger signalling and energy expenditure pathway effects documented in research. Together these three compounds act on adipose pathways from three separate biological mechanisms simultaneously, with research data documenting compounding metabolic effects across published research.

Administration parameters and combination use references for this research combination are documented in published research data. Research period parameters are documented in published research literature.

CJC-1295 is a synthetic GHRH analogue that acts on the pituitary gland to stimulate growth hormone release and extends the duration of GH pulses. Ipamorelin is a selective GHRP that triggers targeted GH release without significantly raising cortisol or prolactin — noted in research as a distinction from older GHRPs like GHRP-6. Together they produce synergistic GH amplification: CJC-1295 widens the GH pulse window while Ipamorelin provides the trigger, with GH output pathway data documented in published research. Research notes the liver converts this GH into IGF-1, with adipose metabolism, muscle protein synthesis, tissue repair, and cellular repair pathway effects documented across research periods.

Reference concentration: 100mcg of each peptide (CJC-1295 + Ipamorelin) per application, as noted in research. Administration timing parameters are documented in published research literature. Food intake timing pathway interactions are documented in published research literature. Research period parameters are documented in published research literature. Often referenced alongside BPC-157, TB-500, or Tesamorelin in published research combinations.

Tesamorelin acts on the pituitary gland to release growth hormone in a natural, pulsatile manner. Research notes elevated GH signals the liver to produce IGF-1, with adipose metabolism, muscle protein synthesis, and tissue repair pathway effects documented in research. Research-documented for visceral adipose reduction and noted in research for cellular repair, body composition, and metabolic pathway data.

Reference concentration: 1.4–2mg daily as noted in research. Administration timing parameters are documented in published research literature. Research period parameters are documented in published research literature. Often referenced alongside BPC-157 or GHK-Cu in published research combinations.

Research documents Human Growth Hormone as having extensive anabolic pathway effects. Research notes it acts on IGF-1 production, lipolysis pathways, muscle protein synthesis, collagen production, and immune function pathways. Somatropin levels are documented to decline with age in published research — with wide-ranging pathway effects on body composition, skin, joints, sleep, and energy documented across research periods.

Reference concentration: 2IU daily as noted in research. Research period parameters are documented in published research literature. Administration timing parameters are documented in published research literature. Administration parameters are documented in published research literature.

HCG binds to the same receptor as LH, acting on Leydig cells and gonadal tissue to stimulate sex hormone production. In male research subjects on hormonal research compounds, research notes it acts on testicular function and intratesticular testosterone pathways relevant to fertility research. Research notes testosterone pathway effects in male subjects with secondary hypogonadism when used as a standalone compound. In female research subjects, research notes progesterone production and ovulation pathway effects.

Reference concentration: 250–500IU 2–3 times per week as noted in research. Concentration parameters for combination and standalone research contexts are documented in published research literature. Stability parameters are documented in published research literature.

GHK-Cu acts on a broad array of regenerative genes — research documents collagen, elastin, and glycosaminoglycan synthesis pathway effects. Research notes wound healing pathway activity, inflammatory signalling reduction, scar tissue remodelling, hair follicle pathway effects, and antioxidant pathway data. Research documents activation of over 4,000 genes associated with cellular restoration and longevity. Endogenous levels are documented to drop approximately 50% between ages 20 and 60 in published research.

Reference concentration noted at 1mg daily as noted in research. Escalation parameters are documented in published research literature. A 30-day washout period between research cycles is documented in published research literature. Often referenced alongside BPC-157 and TB-500 in published research combinations.

NAD+ is a coenzyme present in every living cell, essential for converting food into cellular energy (ATP), repairing damaged DNA, regulating circadian rhythm, and controlling inflammatory signalling. Research notes it activates sirtuins and PARPs — proteins that protect DNA integrity and are associated with biological aging pathways. Research notes subcutaneous administration is documented to deliver higher bioavailability compared to oral administration in published studies.

Reference concentration noted at 25–50mg daily increasing as noted in research up to 100mg+ as noted in research. A mild flushing sensation during application is commonly noted in research and slow application rate is noted to reduce this. Administration timing parameters are documented in published research literature. Often referenced alongside MOTS-C for mitochondrial pathway research. Particularly documented in research involving cellular energy, cognitive pathway, and age-related metabolic pathway studies.

Both deliver the same NAD+ molecule and produce the same cellular pathway activity. The distinction is entirely in the documented application experience in research subject data.

MOTS-C is produced by mitochondria under metabolic stress and travels to the nucleus to regulate gene expression. Research notes it activates AMPK (a key metabolic regulator), with glucose uptake in muscle, adipose reduction, and mitochondrial efficiency pathway effects documented. Studies document physical endurance pathway data, obesity-related inflammatory signalling reduction, and age-related metabolic pathway changes — including in the absence of diet or exercise modifications.

Reference concentration: 1mg daily for 5 days per week, or 5mg 2–3 times per week as noted in research. Research data notes escalation up to 10–15mg per research application in performance-focused research. Research period parameters are documented in published research literature. Often referenced alongside NAD+, Somatropin, and Tesamorelin in comprehensive metabolic and cellular aging research combinations.

Lipo-C is a combination of lipotropic agents that act on fat metabolism in the liver. Research notes methionine acts on fat deposit breakdown pathways. Inositol is documented to act on fat redistribution and cholesterol pathway activity. Choline is noted to act on hepatic fat accumulation pathways and fat transport mechanisms. Research documents that combined with B12 and B-complex vitamins, cellular energy production pathway effects and metabolic clearance mechanisms are noted as observed effects.

Reference concentration: 25–54mg (25 units) 2–3 times per week, as noted in research. Escalation parameters are documented in published research literature. Administration parameters are documented in published research literature. No washout period required. Often referenced alongside semaglutide, tirzepatide, or other metabolic research combinations as a complementary compound.

Glow is referenced in research for dermal matrix, hair follicle, cellular aging, tissue repair, and inflammatory pathway studies. The BPC-157 + TB-500 combination is a peptide tissue repair combination with documented published research data, with GHK-Cu adding regenerative gene expression and dermal pathway data.

Klow builds on Glow by adding KPV, with published research referencing gut pathway, inflammatory signalling, and immune modulation pathway data. The four-peptide combination provides a comprehensive inflammatory signalling and tissue repair research profile.

Reference concentration: 15 units daily as noted in research. Research period parameters are documented in published research literature. Stability parameters are documented in published research literature.

The Wolverine Stack combines TB-500 and BPC-157 — two peptides with complementary tissue repair mechanisms. Research documents TB-500 as acting on systemic tissue repair through cell migration and angiogenesis pathways. Research documents BPC-157 as acting on local tendon, ligament, muscle, and gut tissue repair pathways while reducing inflammatory signalling. Together research documents comprehensive pathway coverage — systemic and local, structural and vascular.

Pre-blended vial — each reference contains both compounds at equal ratio. Three reference tiers noted in research: Tier 1 Reference (general maintenance research): 2.5mg blend · 2x weekly · 4–6 weeks. Tier 2 Reference (active tissue repair research): 5mg blend · 2x weekly · 4–6 weeks, then 2.5mg once weekly. Tier 3 Reference (intensive research): 5mg blend · daily for first 2 weeks, then 5mg · 2–3x weekly for weeks 3–6. Administration parameters are documented in published research literature. Both compounds are present in each administration.

Research documents Sildenafil as acting by blocking PDE5 to increase nitric oxide activity and vasodilation pathway effects. Clinical data notes an extensively documented side effect profile. Food is noted in research to slow absorption. Research data notes it is referenced for acute on-demand administration patterns, compared to Tadalafil's longer-acting profile.

Research reference: 50mg with onset noted at approximately 1 hour in research data. Food noted to slow absorption. Combination with nitrates documented as contraindicated in clinical literature. Headache and flushing are noted side effects in clinical data.

Semax is a synthetic analogue of ACTH (adrenocorticotropic hormone). Research notes it increases BDNF (brain-derived neurotrophic factor), acts on dopamine and serotonin pathway activity, and is documented for neuroprotective pathway effects. Documented in Russian pharmaceutical research for cognitive disorders, neurological research, and ADHD pathway studies. Research data notes cognitive pathway, focus, and mood pathway effects among observed data points.

Reference concentration: 100–300mcg as noted in research. Research period parameters are documented in published research literature. Often referenced alongside BPC-157 for neuroprotective pathway research and NAD+ for comprehensive cognitive pathway research combinations.

Bacteriostatic water (BAC water) is sterile water containing 0.9% benzyl alcohol. The benzyl alcohol prevents bacterial growth, allowing a reconstituted vial to be used multiple times over 28–30 days — unlike regular sterile water which must be used immediately. Research literature documents it as the widely referenced reconstitution solution for research-grade peptides.

The volume of BAC water added determines the concentration. Adding 1mL to a 10mg vial yields 10mg/mL (1mg per 0.1mL). Adding 2mL yields 5mg/mL. The Measurement Calculator is available to determine exact application volumes for a target concentration.

A collagen-infused topical research compound. Research notes collagen peptides applied topically act on skin barrier pathway function, moisture retention pathway effects, and fine line pathway data. Often referenced alongside systemic peptides such as GHK-Cu, NAD+, and Glutathione in published research combinations.

Application parameters are documented in published research literature. Often referenced as the topical component of The Fountain, The Bloom, and The Flawless research combinations.

TB-500 is a synthetic version of Thymosin Beta-4, a protein found throughout the body with a documented role in tissue repair pathway activity. Research notes it works systemically — proximity to the area of interest for administration is not required. TB-500 acts on actin upregulation (critical for cell movement), angiogenesis pathway activity, and inflammatory signalling reduction, with tendon, muscle, ligament, and cardiac tissue repair pathway effects documented in research.

Reference concentration: 2.5mg as noted in research. Escalation parameters are documented in published research literature. Administration parameters are documented in published research literature. Often referenced alongside BPC-157 in published research combinations.

BPC-157 is derived from a protective protein found in gastric juice. Research documents it acts on tissue repair pathway mechanisms including tendon-to-bone repair, growth hormone receptor pathway activity, nitric oxide pathway effects, and inflammatory signalling reduction. Administration parameters are documented in published research literature.

Reference concentration: 250–500mcg daily as noted in research. Administration parameters are documented in published research literature. Research period parameters are documented in published research literature. Often referenced alongside TB-500 in published tissue repair research combinations. Receptor downregulation has not been reported in published research literature to date.

Glutathione is a tripeptide (glycine, cysteine, glutamate) produced by every cell in the body. Research notes it neutralizes free radicals, supports liver detoxification, regenerates vitamins C and E, and regulates melanin production. Research notes subcutaneous administration is documented to deliver higher bioavailability compared to oral administration in published studies.

Reference concentration: 600–1500mg as noted in research, 3–5 times weekly as noted in research. Research notes Vitamin C is frequently co-referenced for absorption pathway and glutathione regeneration effects. Consistent administration over 4–8 weeks is the documented research period in published melanin regulation pathway studies.

SLU-PP-332 is a novel exercise mimetic compound that activates ERR (estrogen-related receptor) pathways — the same pathways activated by endurance exercise. Research data documents fat oxidation, endurance, metabolic rate, and cardiovascular pathway effects as observed data points.

Reference concentration noted at 1 tablet daily in research data. Often noted in combination with other metabolic research agents. For research and educational purposes only.

Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurological conditions and later studied for metabolic pathway effects. Research documents its mechanism as blocking the reuptake of dopamine, serotonin, and norepinephrine — with appetite signalling pathway reduction and increased resting energy expenditure noted as observed effects in research data.

Reference concentration: 0.25–0.5mg daily as noted in research. Escalation parameters are documented in published research literature. Can be referenced in combination with GLP-1 compounds. Extended research period pathway response data is documented in published research literature.

BPC-157 (Research Peptide Compound) in oral tablet form. Research notes the oral route is referenced for gastrointestinal pathway research, gut barrier integrity, and digestive research applications, with systemic tissue repair and inflammatory signalling pathway effects also documented in published studies.

Reference concentration: 1–2 tablets daily as noted in research. Administration parameters are documented in published research literature. Research period parameters are documented in published research literature. Long-term administration side effect profiles are documented in research literature. Often referenced alongside BPC-157 Injectable in published tissue repair research combinations.